Novo Nordisk A/S (NYSE:NVO) Shares Sold by Kanawha Capital Management LLC

Kanawha Capital Management LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 4.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,052 shares of the company’s stock after selling 96 shares during the quarter. Kanawha Capital Management LLC’s holdings in Novo Nordisk A/S were worth $244,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. 1620 Investment Advisors Inc. purchased a new position in Novo Nordisk A/S during the second quarter worth approximately $25,000. Strategic Investment Solutions Inc. IL purchased a new stake in Novo Nordisk A/S during the second quarter worth approximately $25,000. Orion Capital Management LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $26,000. Gilliland Jeter Wealth Management LLC boosted its position in shares of Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares during the period. Finally, Halpern Financial Inc. lifted its position in Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.0 %

Shares of NVO stock opened at $109.72 on Tuesday. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The firm has a market capitalization of $492.37 billion, a PE ratio of 37.58, a price-to-earnings-growth ratio of 1.46 and a beta of 0.43. The stock has a fifty day moving average of $123.74 and a two-hundred day moving average of $130.85. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The business had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. As a group, research analysts expect that Novo Nordisk A/S will post 3.01 EPS for the current year.

Wall Street Analyst Weigh In

NVO has been the subject of a number of recent analyst reports. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, October 10th. Finally, BMO Capital Markets decreased their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.